Highly efficient and safe genome editing by CRISPR-Cas12a using CRISPR RNA with a ribosyl-2'-O-methylated uridinylate-rich 3'-overhang in mouse zygotes

Cited 13 time in scopus
Metadata Downloads

Full metadata record

DC FieldValueLanguage
dc.contributor.authorDae In Ha-
dc.contributor.authorJeongmi Lee-
dc.contributor.authorNan Ee Lee-
dc.contributor.authorDaesik Kim-
dc.contributor.authorJeong Heon Ko-
dc.contributor.authorYong-Sam Kim-
dc.date.accessioned2020-12-29T03:30:18Z-
dc.date.available2020-12-29T03:30:18Z-
dc.date.issued2020-
dc.identifier.issn1226-3613-
dc.identifier.urihttps://oak.kribb.re.kr/handle/201005/23952-
dc.description.abstractThe CRISPR-Cas12a system has been developed to harness highly specific genome editing in eukaryotic cells. Given the relatively small sizes of Cas12a genes, the system has been suggested to be most applicable to gene therapy using AAV vector delivery. Previously, we reported that a U-rich crRNA enabled highly efficient genome editing by the CRISPR-Cas12a system in eukaryotic cells. In this study, we introduced methoxyl modifications at C2 in riboses in the U-rich 3'-overhang of crRNA. When mixed with Cas12a effector proteins, the ribosyl-2'-O-methylated (2-OM) U-rich crRNA enabled improvement of dsDNA digestibility. Moreover, the chemically modified U-rich crRNA achieved very safe and highly specific genome editing in murine zygotes. The engineered CRISPR-Cas12a system is expected to facilitate the generation of various animal models. Moreover, the engineered crRNA was evaluated to further improve a CRISPR genome editing toolset.-
dc.publisherSpringer-Nature Pub Group-
dc.titleHighly efficient and safe genome editing by CRISPR-Cas12a using CRISPR RNA with a ribosyl-2'-O-methylated uridinylate-rich 3'-overhang in mouse zygotes-
dc.title.alternativeHighly efficient and safe genome editing by CRISPR-Cas12a using CRISPR RNA with a ribosyl-2'-O-methylated uridinylate-rich 3'-overhang in mouse zygotes-
dc.typeArticle-
dc.citation.titleExperimental and Molecular Medicine-
dc.citation.number11-
dc.citation.endPage1830-
dc.citation.startPage1823-
dc.citation.volume52-
dc.contributor.affiliatedAuthorDae In Ha-
dc.contributor.affiliatedAuthorJeongmi Lee-
dc.contributor.affiliatedAuthorNan Ee Lee-
dc.contributor.affiliatedAuthorDaesik Kim-
dc.contributor.affiliatedAuthorJeong Heon Ko-
dc.contributor.affiliatedAuthorYong-Sam Kim-
dc.contributor.alternativeName하대인-
dc.contributor.alternativeName이정미-
dc.contributor.alternativeName이난이-
dc.contributor.alternativeName김대식-
dc.contributor.alternativeName고정헌-
dc.contributor.alternativeName김용삼-
dc.identifier.bibliographicCitationExperimental and Molecular Medicine, vol. 52, no. 11, pp. 1823-1830-
dc.identifier.doi10.1038/s12276-020-00521-7-
dc.description.journalClassY-
Appears in Collections:
Critical Diseases Diagnostics Convergence Research Center > 1. Journal Articles
Synthetic Biology and Bioengineering Research Institute > Genome Editing Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.